SCHEMBL2428527

SCHEMBL2428527

CC(C)(C)c1cc(CCc2cc(CCc3ccc(-c4ccc(F)cc4F)nc3)cc(CCc3cc(C(C)(C)C)cc(C(C)(C)C)c3)c2)cc(C(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 2/20 0.43
▸ GRM2 Q14416 6/20 0.40
▸ DHODH Q02127 1/20 0.37
▸ CYP11B1 P15538 3/20 0.37
▸ CYP11B2 P19099 1/20 0.37
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ TP53 P04637 2/20 0.36
▸ NFKB1 P19838 2/20 0.36
▸ NFKB2 Q00653 2/20 0.36
▸ RELA Q04206 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ CYP2C9 P11712 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14268238 0.88 GRM2 (0.47) GRM2DHODHCYP11B1CYP11B2NPC1
SCHEMBL25100819 0.82 GRM2 (0.51) GRM2DHODHCYP11B1CYP11B2NPC1
SCHEMBL15602058 0.81 GRM2 (0.45) GRM2DHODHCYP11B1CYP11B2NPC1
SCHEMBL8515855 0.80 SMN1; SMN2 (0.55) GRM2DHODHCYP11B1CYP11B2NPC1
SCHEMBL2430228 0.78 ALOX5AP (0.43) ALOX5APGRM2DHODHL3MBTL1CASP3
SCHEMBL15060602 0.77 GRM2 (0.47) ALOX5APGRM2DHODHCYP11B1CYP11B2
SCHEMBL25100958 0.75 LPL (0.37) GRM2DHODHCYP11B1CYP11B2NPC1
SCHEMBL20019514 0.74 NPC1 (0.42) ALOX5APGRM2DHODHCYP11B1NPC1
SCHEMBL13017141 0.73 GRM2 (0.45) ALOX5APGRM2DHODHCYP11B1CYP11B2
SCHEMBL9325558 0.72 SMN1; SMN2 (0.55) ALOX5APGRM2CYP11B1CYP11B2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546284-B1 REACTIVE DENDRIMERS UNIV OXFORD INNOVATION LTD (GB) 2018-04-04 — — EP disclosed
US-8025988-B2 Reactive organometallic dendrimers ISIS INNOVATION LIMITED (GB) 2011-09-27 — — US disclosed
US-20100228022-A1 Reactive Organometallic Dendrimers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2010-09-09 — — US disclosed
US-7740954-B2 Reactive dendrimers ISIS INNOVATION LIMITED (GB) 2010-06-22 — — US disclosed
US-20050164029-A1 Reactive dendrimers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2005-07-28 — — US disclosed
EP-1546284-A1 REACTIVE DENDRIMERS ISIS INNOVATION LIMITED (GB) 2005-06-29 — — EP disclosed
WO-2004020547-A1 REACTIVE DENDRIMERS ISIS INNOVATION LIMITED (GB) 2004-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228022-A1 Reactive Organometallic Dendrimers ITGAM, CD40LG, DBN1 ALOX5AP 328/4885GRM2 44/4885DHODH 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback